Clinical trials: sponsored by Amgen
Chronic Kidney Disease
EPO Deep Tank in Dialysis Subjects
Subject incidence of adverse events
- Trial name
- NCT00156949
- Testing
- Epoetin alfa DT
- Volunteers
- 580 people
- Sponsor
- Amgen
Idiopathic Parkinson's Disease
A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin
The primary purpose of this study is to evaluate clinical and serologic outcomes after the discontinuation of liatermin therapy as assessed by development of new clinical conditions beyond those expected in patients with…
- Trial name
- NCT00148369
- Testing
- Safety observation
- Volunteers
- 31 people
- Sponsor
- Amgen
Myelodysplastic Syndromes
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).
- Trial name
- NCT00095264
- Testing
- Darbepoetin Alfa
- Volunteers
- 209 people
- Sponsor
- Amgen
Anemia, Non-Myeloid Malignancies
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
The purpose of this study is to compare the effect of darbepoetin alfa against placebo for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.
- Trial name
- NCT00110955
- Testing
- Darbepoetin alfa
- Volunteers
- 391 people
- Sponsor
- Amgen
Rheumatoid Arthritis
The SPECTRA Study
The purpose of this study is to compare IL-1ra and the combination of IL-1ra and PEGsTNF-RI with respect to their ability to reduce inflammation and bone and cartilage destruction in the synovium of subjects with rheumatoid…
- Trial name
- NCT00537667
- Testing
- anakinra, anakinra and PEG sTNF-R1
- Volunteers
- 22 people
- Sponsor
- Amgen
Juvenile Chronic Arthritis
Juvenile Rheumatoid Arthritis
The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.
- Trial name
- NCT00037648
- Testing
- Anakinra
- Volunteers
- 86 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire
The primary purpose of this study is to assess the ease-of-use of SimpleJectTM compared to pre-filled syringe(s) when using Kineret® in RA subjects.
- Trial name
- NCT00121043
- Testing
- SimpleJectTM, Kineret® (Anakinra)
- Sponsor
- Amgen
Rheumatoid Arthritis
Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis
The purpose of this study is to evaluate the effect of anakinra (IL-1 ra) and pegsunercept (PEG sTNF-RI) when they are used together in improving the signs and symptoms of rheumatoid arthritis.
- Trial name
- NCT00037700
- Testing
- anakinra, pegsunercept
- Sponsor
- Amgen
Rheumatoid Arthritis
Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)
The purpose of this study is to evaluate the proportion of Rheumatoid Arthritis (RA) subjects achieving a "good" or "moderate" DAS28 response (EULAR28 criteria) at Week 16 with etanercept 50 mg subcutaneously (SC) once weekly in…
- Trial name
- NCT00099554
- Testing
- Etanercept
- Volunteers
- 200 people
- Sponsor
- Amgen
Chronic Kidney Disease, Chronic Renal Insufficiency
STAAR-1 Clinical Study
To assess the effect of Aranesp on the hemoglobin of CRI subjects who are recombinant human erythropoetin (rHuEPO)-naïve or converting from rHuEPO therapy
- Conditions
- Chronic Kidney Disease, Chronic Renal Insufficiency, Kidney Disease, Pre-dialysis
- Trial name
- NCT00369772
- Testing
- darbepoetin alfa
- Volunteers
- 2,000 people
- Sponsor
- Amgen
Anemia, Congestive Heart Failure
A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects
The purpose of this study is to evaluate the single dose pharmacokinetics (PK) of subcutaneous (SC) darbepoetin alfa in subjects with congestive heart failure (CHF) and anemia.
- Trial name
- NCT00117247
- Testing
- darbepoetin alfa
- Volunteers
- healthy volunteers welcome
- Sponsor
- Amgen
End Stage Renal Disease
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis
The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinant human erythropoietin (rHuEPO) naïve or…
- Trial name
- NCT00117104
- Testing
- Aranesp®
- Sponsor
- Amgen
Metastatic Colorectal Cancer
Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
The primary objective of this study is to assess the effect of treatment with ABX-EGF on best overall objective response rate by modified RECIST (confirmed complete or partial response) in Japanese subjects with metastatic…
- Trial name
- NCT00327119
- Testing
- ABX-EGF (panitumumab)
- Volunteers
- 50 people
- Sponsor
- Amgen
Heart Failure, Anemia
Heart Failure and Anemia
The purpose of this study is to determine whether increasing hemoglobin concentration in patients with heart failure and anemia will improve the patients' functional status, including exercise tolerance and New York Heart…
- Trial name
- NCT00049985
- Testing
- Darbepoetin Alfa
- Volunteers
- 300 people
- Sponsor
- Amgen
Non-Hodgkin's Lymphoma
Treatment for Subjects With Non-Hodgkin's Lymphoma
This multicenter, open-label, randomized, parallel study was designed to evaluate whether a single fixed-dose subcutaneous (SC) administration of pegfilgrastim or daily administration of Filgrastim for absolute neutrophil count…
- Trial name
- NCT00117897
- Testing
- pegfilgrastim, Filgrastim
- Sponsor
- Amgen
Chronic Kidney Disease, Kidney Disease
Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients not on dialysis.
- Trial name
- NCT00112008
- Testing
- De Novo Administration of Darbepoetin Alfa
- Volunteers
- 100 people
- Sponsor
- Amgen
Tumors, Oncology
Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.
- Conditions
- Tumors, Oncology, Solid Tumors
- Trial name
- NCT00091806
- Testing
- panitumumab (ABX-EGF), Panitumumab
- Volunteers
- 86 people
- Sponsor
- Amgen
Psoriasis
An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis
The purpose of this multicenter, open-label, prospective study is to evaluate the effectiveness and safety of etanercept in the treatment of subjects with psoriasis.
- Trial name
- NCT00111111
- Testing
- Etanercept
- Sponsor
- Amgen
Pre-Dialysis
Fixed Dose NESP Study in Subjects With CRI
Multicenter, open-label, single-arm, fixed dose study of darbepoetin alfa in subjects with Chronic Renal Insufficiency (CRI). Subjects will be screened for 2 weeks during which time blood will be drawn and vital signs will be…
- Trial name
- NCT00526929
- Testing
- darbepoetin alfa
- Volunteers
- 75 people
- Sponsor
- Amgen
Pre-Dialysis
Phase 2 Study of Darbepoetin Alfa Extended Dosing
Multicenter, open label single arm study in which 140 subjects with CRI who are currently receiving SC darbepoetin alfa once every other week will receive darbepoetin alfa once every 4 weeks for 24 weeks.
- Trial name
- NCT00527215
- Testing
- darbepoetin alfa
- Volunteers
- 98 people
- Sponsor
- Amgen